These actions contain class-broad basic safety labeling alterations and new submit-advertising and marketing necessities for all ER/LA opioid analgesics. FDA also responded to two citizen petitions pertaining to labeling of opioids. March: On March 19, FDA took motion against marketer of unapproved solutions boasting to deal with habit, Long-term